Published in Mov Disord on October 01, 2004
Parkinsonism and inborn errors of metabolism. J Inherit Metab Dis (2014) 1.40
Parkinsonism in phenylketonuria: a consequence of dopamine depletion? JIMD Rep (2015) 0.81
Parkinsonism in Association with Dihydropteridine Reductase Deficiency. Case Rep Neurol (2017) 0.75
Characterization of tremor in phenylketonuric patients. J Neurol (2005) 0.75
Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia (2005) 9.32
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81
Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nat Genet (2006) 5.59
Syllabus for Postgraduate Specialization in Nuclear Medicine--2011/2012 Update: nuclear medicine training in the European Union. Eur J Nucl Med Mol Imaging (2012) 4.93
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet (2002) 4.42
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain (2002) 4.16
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol (2005) 2.94
Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord (2004) 2.84
The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol (2003) 2.80
Lack of association between progressive supranuclear palsy and arterial hypertension: a clinicopathological study. Mov Disord (2003) 2.69
Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain (2005) 2.67
Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain (2003) 2.63
Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol (2003) 2.61
Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol (2010) 2.60
Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol (2006) 2.56
ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord (2010) 2.47
Parkin disease: a phenotypic study of a large case series. Brain (2003) 2.41
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol (2009) 2.38
Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord (2010) 2.36
PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One (2008) 2.33
Statins and myopathy. Lancet (2002) 2.21
The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain (2004) 2.20
Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain (2010) 2.19
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain (2003) 2.17
Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol (2012) 2.08
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Mov Disord (2012) 2.02
Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord (2007) 1.96
Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem (2006) 1.91
A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain (2011) 1.89
The cycling of acetyl-coenzyme A through acetylcarnitine buffers cardiac substrate supply: a hyperpolarized 13C magnetic resonance study. Circ Cardiovasc Imaging (2012) 1.86
What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord (2010) 1.80
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol (2010) 1.80
Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord (2004) 1.76
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord (2012) 1.75
The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology (2013) 1.74
Neuropathological findings in benign tremulous parkinsonism. Mov Disord (2012) 1.74
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer (2008) 1.72
Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol (2011) 1.71
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord (2011) 1.70
Natural history and syndromic associations of orthostatic tremor: a review of 41 patients. Mov Disord (2004) 1.69
Parkin disease: a clinicopathologic entity? JAMA Neurol (2013) 1.68
Progressive supranuclear palsy: where are we now? Lancet Neurol (2002) 1.65
The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil. Mov Disord (2008) 1.65
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol (2012) 1.61
Detection of tumour thrombus by 18F-FDG-PET/CT imaging. Eur J Cancer Prev (2007) 1.59
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging (2010) 1.56
Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord (2010) 1.56
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry (2007) 1.52
Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain (2007) 1.52
Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord (2007) 1.52
Clinical features of childhood-onset paroxysmal kinesigenic dyskinesia with PRRT2 gene mutations. Dev Med Child Neurol (2013) 1.51
J. Clifford Richardson and 50 years of progressive supranuclear palsy. Neurology (2008) 1.50
Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol (2003) 1.48
Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry (2012) 1.47
Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain (2006) 1.47
In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol (2010) 1.47
Olfactory impairment in familial ataxias. J Neurol Neurosurg Psychiatry (2012) 1.44
Antioxidants, reactive oxygen and nitrogen species, gene induction and mitochondrial function. Mol Aspects Med (2002) 1.43
Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci (2009) 1.43
Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. Brain (2010) 1.43
Opsoclonus myoclonus syndrome associated with GQ1b antibodies. Mov Disord (2012) 1.43
Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology (2010) 1.42
Reporting clinical trials: full access to all of the data. Arch Neurol (2002) 1.39
Late onset ataxia: MSA-C or SCA 17? A gene penetrance dilemma. Mov Disord (2013) 1.39
GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc Res (2002) 1.38
Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse. Circulation (2005) 1.38
Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord (2007) 1.35
Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain (2010) 1.34
Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs (2009) 1.32
Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol (2004) 1.31
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain (2002) 1.30
The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol (2011) 1.30
Measuring intracellular pH in the heart using hyperpolarized carbon dioxide and bicarbonate: a 13C and 31P magnetic resonance spectroscopy study. Cardiovasc Res (2009) 1.24
Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol (2004) 1.24
Pathophysiological differences between musician's dystonia and writer's cramp. Brain (2005) 1.23
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord (2014) 1.23
Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain (2011) 1.22
Motor inhibition in patients with Gilles de la Tourette syndrome: functional activation patterns as revealed by EEG coherence. Brain (2004) 1.21
The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord (2014) 1.21
Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Exp Neurol (2006) 1.20
Normal pressure hydrocephalus or progressive supranuclear palsy? A clinicopathological case series. J Neurol (2012) 1.18
Pyridoxal 5'-phosphate values in cerebrospinal fluid: reference values and diagnosis of PNPO deficiency in paediatric patients. Mol Genet Metab (2008) 1.17
Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord (2008) 1.17
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain (2004) 1.16
Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol (2008) 1.15